HCV Medication Receipt Among Individuals With Methamphetamine, Opioid, and Alcohol Use Disorders in Arkansas, 2018–2022: A Long Road Ahead for HCV Elimination in the US South
George Pro, Corey Hayes, Jonathan Bona, Mofan Gu, Camille Richoux, N. Zaller
{"title":"HCV Medication Receipt Among Individuals With Methamphetamine, Opioid, and Alcohol Use Disorders in Arkansas, 2018–2022: A Long Road Ahead for HCV Elimination in the US South","authors":"George Pro, Corey Hayes, Jonathan Bona, Mofan Gu, Camille Richoux, N. Zaller","doi":"10.1177/00220426241231720","DOIUrl":null,"url":null,"abstract":"Background. Methamphetamine and opioid use disorders (MUD/OUD) are increasing in the US, paralleled by a surge in hepatitis C virus (HCV). HCV is curable with direct-acting antiviral medication (DAA), but people with HCV who use drugs often don’t receive it. We estimated differences in DAA by substance type among people with HCV in Arkansas. Methods. We used a statewide medical claims database to identify HCV cases who also had MUD, OUD, and/or AUD (pooled 2018–2022; N = 5439). We used multiple logistic regression to model DAA receipt, adjusted for relevant covariates. Results. Only 10% of our sample received DAA. The lowest predicted probabilities of DAA receipt were among people who used methamphetamine (4.5%) and those covered by Medicaid (5.4%). Conclusion. Arkansas Medicaid has the strictest requirements for initiating DAA in the country. Public health efforts that reduce exposure to HCV among people who use drugs will reduce the HCV burden in Arkansas.","PeriodicalId":15626,"journal":{"name":"Journal of Drug Issues","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Issues","FirstCategoryId":"90","ListUrlMain":"https://doi.org/10.1177/00220426241231720","RegionNum":4,"RegionCategory":"社会学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SUBSTANCE ABUSE","Score":null,"Total":0}
引用次数: 0
Abstract
Background. Methamphetamine and opioid use disorders (MUD/OUD) are increasing in the US, paralleled by a surge in hepatitis C virus (HCV). HCV is curable with direct-acting antiviral medication (DAA), but people with HCV who use drugs often don’t receive it. We estimated differences in DAA by substance type among people with HCV in Arkansas. Methods. We used a statewide medical claims database to identify HCV cases who also had MUD, OUD, and/or AUD (pooled 2018–2022; N = 5439). We used multiple logistic regression to model DAA receipt, adjusted for relevant covariates. Results. Only 10% of our sample received DAA. The lowest predicted probabilities of DAA receipt were among people who used methamphetamine (4.5%) and those covered by Medicaid (5.4%). Conclusion. Arkansas Medicaid has the strictest requirements for initiating DAA in the country. Public health efforts that reduce exposure to HCV among people who use drugs will reduce the HCV burden in Arkansas.
期刊介绍:
The Journal of Drug Issues (JDI) was incorporated as a nonprofit entity in the State of Florida in 1971. In 1996, JDI was transferred to the Florida State University College of Criminology and Criminal Justice, and the Richard L. Rachin Endowment was established to support its continued publication. Since its inception, JDI has been dedicated to providing a professional and scholarly forum centered on the national and international problems associated with drugs, especially illicit drugs. It is a refereed publication with international contributors and subscribers. As a leader in its field, JDI is an instrument widely used by research scholars, public policy analysts, and those involved in the day-to-day struggle against the problem of drug abuse.